Chronic Pain Patients Should Leverage Election Year
Patient advocate Monty Goddard provides a template for chronic pain patients to use to advocate as constituents to their elected ...
Why I’m Running for the Arizona State Legislature
Serving as the LD7 State Representative will help me move forward to make a difference in healthcare through legislation and ...
Celebrating My Brother’s Life
My brother died of an overdose from illicit fentanyl. Many would be ashamed to discuss this. I choose to be ...
Endorse Barby Ingle!
Barby Ingle is the ideal candidate for the position of Arizona State Representative District 7. We endorse her nomination!
Physicians: Protect your Credentials
Doctors and other providers are at risk of identity theft and misuse of their medical credentials and licensure.
Disabled, Elderly Patients Set to Overwhelm Healthcare
The number of older adults with disabilities will soar in the decades ahead and the healthcare system will be overwhelmed.
Getting a Colonoscopy in Prison
Incarcerated individuals find themselves caught in an intricate web of inadequate healthcare and limited access to screening tests.
Has the Biden Administration Abandoned Doctors?
Even the CDC and DHHS acknowledge that it is legal to treat pain in someone with addiction, as long as ...
Rise of Cash Pay Drugs
With medication costs surpassing household incomes, a growing number of individuals are exploring alternative ways to access medicines.
How Patients Can Retake the Emergency Care Experience
The narratives of patients experiencing pain in Emergency Rooms highlight a pivotal concern in the healthcare landscape.
Unsung Heroes of Organ Transplants
Many a time, we celebrate the remarkable stories of survival and revival that organ transplants bring to life.
AI Startups Offer Teletherapy
The patients didn’t care when the chatbot said “I understand how you’re feeling” because they knew it was an empty, ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more